Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering ...
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit ...
The FDA approved oral vepdegestrant (Veppanu) for adults with advanced or metastatic estrogen receptor (ER)-positive/HER2-negative breast cancer, the agency announced ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results